Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)

Fig. 1

Effects of GLP-1 agonists on vascular endothelium*. NOX-4 (NADPH oxidase 4), LOX-1 (lectin-like ox-LDL receptor-1), ROS (reactive oxygen species), oxLDL (oxidized LDL), VCAM-1 (vascular cell adhesion molecule-1), ICAM-1 (intercellular adhesion molecule-1), NO (nitric oxide), eNOS (endothelial nitric oxide synthase), AMPK (AMP-activated protein kinase), NLRP3 (NOD-like receptor family, pyrin domain-containing 3), PPARγ (peroxisome proliferator-activated receptor γ). The GLP-1 agonists effects demonstrated in this figure are mediated through GLP-1 receptors in the vascular endothelium. *This illustration was created using Servier Medical Art for medical illustrations

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840